What is the difference between Lamisil and Lotrimin?
By
Dr Drielli Vital-Fujii (PhD)
Author bio
Dr Drielli Vital-Fujii, PhD, is a Pharmacist with expertise in Drug Design and Development, Enzymes, Molecular Modelling, and Photodynamic Therapy. She writes and reviews content on these topics.
Dr Drielli Vital-Fujii’s Highlights:
- Postdoctoral fellow at the Department of Biochemistry at the University of São Paulo, emphasizing therapy of neglected diseases using light.
- PhD in Pharmaceutical Sciences focusing on drug design and development at the Faculty of Pharmaceutical Sciences of the University of São Paulo.
- Six months as an international researcher at the Center for Discovery and Innovation in Parasitic Diseases (University of California San Diego)
- Master’s degree in Pharmaceutical Sciences focusing on drug design and development at the Faculty of Pharmaceutical Sciences of the University of São Paulo.
- Bachelor of Pharmacy at the University of Mogi das Cruzes – São Paulo / Brazil
Professional Experience:
2012 – 2018 Project manager at University of São Paulo – Pharmacy Department
Dr Drielli Vital-Fujii has worked with computational studies, synthesis, biological evaluation, design, and development of new inhibitor candidates for Chagas Disease and Leishmaniasis.
2017 – 2017 International research fellow at University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences – Center for Discovery and Innovation in Parasitic Diseases.
She used Virtual Screening (VS) and High-Throughput Screening (HTS) Integration in the Discovery of new drugs against neglected tropical diseases (NTDs).
2018 – 2019 Faculdades Oswaldo Cruz
Dr Drielli Vital-Fujii was a professor in the Faculty of Pharmacy, teaching the subjects of Pharmaceutical Chemistry and Drug Development.
2019 – 2021 Researcher in Biochemistry University of São Paulo – Biochemistry Department
She applied Photodynamic Therapy in Leishmaniasis Treatment, mentored undergraduate students in scientific activities, and wrote, executed, translated, and reported scientific projects with funding agencies.
2023-2023 UniPiaget – University Center.
Dr Drielli Vital-Fujii was a Biology, Nutrition, Physiotherapy, and Pharmacy professor.
Education:
2018 -2021 Postdoctoral at the Department of Biochemistry at the University of São Paulo
2013 -2018 PhD of Science: Drugs and Medicines at Department of Pharmacy at University of São Paulo
2012 -2013 M.Sc. of Sciences: Drugs and Medicines at the Department of Pharmacy at the University of São Paulo
2005-2008 Bachelor of Pharmacy at the University of Mogi das Cruzes
The leading publications of Dr Drielli Vital-Fujii are:
Vital-Fujii, D.G, Baptista, M.S. (2021). Progress in the photodynamic therapy treatment of Leishmaniasis. Brazilian Journal of Medical and Biological Research, 54, 1-11.
Gatti, F. M., Gomes, R.A., da Fonseca, A.L., Lima, E.J.C., Vital-Fujii, D.G., Taranto, A.G., Varotti, F.P., Trossini, G.H.G. (2020). Antiplasmodial activity of sulfonylhydrazones: in vitro and in silico approaches. Future medicinal chemistry, 13, 233-250.
Silva, E.J., Bezerra-Souza, A., Passero, L.F., Laurenti, M.D., Ferreira, G.M., Fujii, D.G.V., et al. (2018). Synthesis, leishmanicidal activity, structural descriptors and structure-activity relationship of quinoline derivatives. Future medicinal chemistry, 10, 2069-2085.
Leite, F.H.A., Froes, T.Q., da Silva, S.G., de Souza, E.I.M., Vital-Fuji,i D.G., Trossini, G.H.G., et al. (2017). An integrated approach towards the discovery of novel non-nucleoside Leishmania major pteridine reductase 1 inhibitors. European Journal of Medicinal Chemistry, 132, 322-332.
Vital, D.G., Damasceno, F.S., Rapado, L.N., Silber, A.M., Vilella, F.S., Ferreira, R.S., et al. (2017). Application of bioisosterism in design of the semicarbazone derivatives as cruzain inhibitors: a theoretical and experimental study. Journal of Biomolecular Structure and Dynamics, 35, 1244–1259.
Mello, J. F.R., Gomes, R.A., Vital-Fujii, D.G., Ferreira, G.M., Trossini, G.H.G. (2017). Fragment-based drug discovery as alternative strategy to the drug development for neglected diseases. Chemical Biology & Drug Design, 90, 1067-1078.
Pantaleao, S.Q., Fujii, D.G.V., Maltarollo, V.G., da C. Silva, D., Trossini, G.H.G., Weber, K.C., et al. (2017). The Role of QSAR and Virtual Screening Studies in Type 2 Diabetes Drug Discovery. Medicinal Chemistry, 13, 706-720.
Vital, D., Arribas, M., Trossini, G. (2014). Molecular Modeling and Docking Application to Evaluate Cruzain Inhibitory Activity by Chalcones and Hydrazides. Letters in Drug Design and Discovery, 11, 249-255.
Blau, L., Menegon, R.F., Trossini, G.H.G., Molino, J.V.D., Vital, D.G., Cicarelli, R.M.B., et al. (2013). Design, synthesis and biological evaluation of new aryl thiosemicarbazone as antichagasic candidates. European Journal of Medicinal Chemistry, 67, 142-151.
You can view some of Dr Drielli’s work below and links to her professional profile.
Orcid: https://orcid.org/0000-0001-9270-0466
Research Gate: https://www.researchgate.net/profile/Drielli-Gomes-Vital-Fujii
Scopus: https://www.scopus.com/authid/detail.uri?authorId=55829534000
Google Scholar: https://scholar.google.com/citations?user=F9U50AEAAAAJ&hl=pt-BR
Linkedin: linkedin.com/in/driellivital
Escavador: https://www.escavador.com/sobre/6101380/drielli-gomes-vital
CDIPD: https://cdipd.org/index.php/about-us/visiting-scientists
What is the difference between Lamisil and Lotrimin?
Lamisil and Lotrimin differ in a number of ways. Let’s take a look at them (1,2):
| Traits | Lamisil | Lotrimin |
|---|---|---|
| Nature | Antifungal | Antifungal |
| Active pharmaceutical ingredient | Terbinafine | Clotrimazole (most common)Butenafine Miconazole Tolnaftate |
| Route of administration | Topical | Topical |
| Mechanism of action | Fungicidal – kills the infection-causing fungi | Fungistatic – inhibits the growth of infection-causing fungi |
| Treatment duration | 1-3 weeks, depending on the severity | 2-5 weeks, depending on the severity |
Both of these topical antifungal preparations are available over-the-counter and they are used in the treatment and management of skin diseases like Athlete’s foot, ringworm, and Jock itch.
They are available in various forms, including creams, sprays, powders, and gels. It is important to use these medications consistently and complete the full course of treatment, even if symptoms improve before completing the prescribed duration (1,2).
Always follow the instructions provided by your healthcare provider or the product label. If you have any concerns or questions about using Lamisil or Lotrimin, consult a healthcare professional.
It is important to seek medical attention if your condition worsens or does not improve after using the medication or if you experience any signs of an allergic reaction, such as rash, itching, swelling, etc.
How to choose between Lamisil and Lotrimin?
When choosing between Lamisil and Lotrimin for treating fungal skin infections, the following factors are considered (1,2):
- Type of infection: Determine the specific type of fungal infection you have. Lamisil is effective against certain types of fungal infections, while Lotrimin is more suitable for others. Your healthcare provider can help identify the type of infection and recommend the appropriate treatment. For example, Lamisil is considered the drug of choice for toenail fungus.
- Symptoms and severity: Assess the severity of your symptoms. If your infection is mild and localized, Lotrimin may be sufficient. However, for more persistent or severe infections, Lamisil might be a better option due to its broader antifungal properties.
- Product form: Both Lamisil and Lotrimin come in various forms, such as creams, sprays, and powders. Choose the product form that is most convenient for you to apply to the affected area.
- Personal preference: Some people may have a personal preference for one product over the other based on past experiences or recommendations from healthcare professionals or friends.
- Medical history: Inform your healthcare provider about any existing medical conditions or allergies you have to ensure that the chosen antifungal medication is safe for you to use. Lamisil can damage the liver and such medications are not recommended for people with pre-existing liver diseases.
- Drug interactions: If you are taking other medications, discuss potential drug interactions with your healthcare provider to avoid any adverse effects.
Final words
To sum up, Lamisil and Lotrimin differ from one another in some ways, although they both are topical anti-fungal medications. However, they both can be used for the relief of similar symptoms.
Make sure you talk to your doctor or pharmacist if you are confused about using the right type of antifungal medication.
Was this helpful?
References
1.-
Maxfield L, Preuss CV, Bermudez R. Terbinafine. 2023 May 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 31424802. https://www.ncbi.nlm.nih.gov/books/NBK545218
2.-
Khatter NJ, Khan MAB. Clotrimazole. 2022 Jul 11. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 32809478. https://www.ncbi.nlm.nih.gov/books/NBK560643
